1st Quarter Financial Results for FYE/Mar 2009

Terumo Corporation
30, July 2008
1Growth trend steady in spite of NHI price down and impactof foreign exchange(Unit: Billion yen)
Q1 FYE/Mar. 2008

Net Sales

Q1 FYE/Mar. 2009

Rate ofchange

75.5

77.8

3%

Gross profit(%)

41.5 (55.0%)

42.2 (54.3%)

2%

S.G.A Expenses(%)

24.5 (32.5%)

26.0 (33.4%)

6%

Operating Income (%) 17.0 (22.5%)

16.2 (20.9%) -4%

Ordinary Income (%) 18.6 (24.6%)

18.9 (24.2%)

1%

13.1

14.07%

US$ 121 yen
EUR 163 yen

105 yen163 yen

Net Income
Average exchange rate

13.5% yen appreciation
0.4% yen depreciation
2

Net Sales (by Region)(Unit: Billion yen)

+ 2%

Q1 FYEQ1 FYE
Mar. 2008 Mar. 2009

Outside Japan total

+ 0.8

+ 4%
(+ 13% excluding impact of foreign exchange)
Ratio of sales outside Japan to total sales

48% Æ 49%

39.1 39.9

+ 12%

- 4%

+ 5%

(+ 13%)+ 1.7(+ 11%)(+ 16%)

14.3 16.0

Japan

Europe‐ 0.6

14.5 13.9

Americas

+ 0.3

7.6

7.9

Asia3

Net Sales (by Product Group)+ 1%+ 6%(+ 2%)(+ 13%)(Unit: Billion yen)

Q1 FYE
Mar. 2008

Q1 FYE
Mar. 2009

+0.3
+ 1.9

36.9

33.1

37.2+ 7%(+ 11%)
+0.3

31.2

- 19%
6.2

(- 19%)

5.9
‐0.3

1.5

GeneralHospital

Cardiac &VascularBloodtransfusion

1.2Consumer
Healthcare 4

S.G.A Expenses(Unit: Billion yen)

+1.5

S.G.A Expenses ratio
0.9 point increase

24.5

26.0
Personnel

32.5%

Q1 FYE/
Mar. 2008

33.4%

Q1
Q1FYE/Mar. FYE/Mar. Change % change
2008
2009
9.3
9.6
0.3
4.1%

Logistics

2.1

2.3

0.2

7.5%

Sales promotion & advertising

2.32.50.2

7.1%

R&D

3.8

3.8--1.9%

Others

7.0

7.8

0.8

12.3%

Total

24.5

26.0

1.5

6.1%

Q1 FYE/
Mar.2009
5The impact of external factors(Unit: Billion yen)

Sales

Operating Profit

８２.８

1９.３

Foreign Exchange
10％

Hepaflush
Revised NHI price

- 5.0

1４％

Foreign Exchange
Hepaflush
Revised NHI price
Changing the accounting &tax system

-3.1
75.5

Q1 FYE/
Mar. 2008

77.8

17.0
16.2

Q1 FYE/
Mar.2009

Q1 FYE/
Mar. 2008

Q1 FYE/
Mar.2009

6Growth steady on truck for annual forecast(Unit: Billion yen)
FYE/Mar 2009

FYE/Mar. 2009

Q1 Results

Annual Forecast

Net Sales

77.8

318.0

Operating Income (%)

16.2 (20.9%)

68.0 (21.4%)

Ordinary Income (%)

18.9 (24.2%)

68.0 (21.4%)

Net Income

14.0

45.0

Average exchangerate

US$ 105 yen
EUR 163 yen

100 yen
155 yen7Topics

8

Costs increasing due to soaring material prices,transportation charges and new regulations in Japan◆Steep price rise of plastic materials & I.V. substances‐ PP, PE Packaging material & amino acids◆Increase in transportation charges‐ Ocean freight (for exports)‐ Storage in Japan◆New regulation in Japan(amended Pharmaceutical Affairs Law)
‐ Indication of specification, material and packing
material changes
9Strengthen the growth of the interventional business
PTCA balloon catheter（Oct. 2007 launched）
Ultrasound diagnostic catheter

ViewIT（Apr. 2008 launched ）19%28%（Sep. 2007）（Jun. 2008）

12%20%（Mar. 2008）（Mar. 2009 forecast）※ Transition in Japanese share of PTCA balloon and ultrasound diagnostic catheters （Terumo estimate）

10

Acquired all shares of Clinical Supply Co., Ltd.
‐ Strengthen radiology business in Japan‐ Globally deploy Clinical Supply products‐ New product development taking advantage of thestrengths of Terumo and Clinical Supply

Micro catheter(Treatment of liver cancer, etc.)

Angiographic catheter
11

Europe driving growth◆Interventional products in particular seeing large sales growth
Sales of Interventional products in Europe
EastEurope &Russia

WesternEurope

6%

9%

6.9

5.5

billion yen

billion yen+25%
Q1 FYE Mar. 2008

Q1 FYE Mar. 200912

Further enhancement of the product line-up in Europe◆Peripheral stent “Misago”‐Released in January 2008
‐Expanding applications of stents todomains other than the heart

Treatment for femoral arteryand other obtrusions◆Automatic centrifugal separation system, “TACSI”‐Launch to go into full effectfrom October 2008
‐High value added bloodtransfusion systems
13

Sales of blood transfusion systems steadily expanding◆Japanese apheresis equipment, “TERUSYS” enjoying favorable sales◆Sales of sterile tube connecting devices (TSCD) increasing◆Increasing demand for blood bags in Asia, showing high growth rates
in India and the Middle East

14
Booth at the general assembly of International Society Blood Transfusion (ISBT): Macao, June 2008

Global development making steady progress◆「Nobori」‐ Europe: 3,000 post-marketing clinical trials started
Announced at academic conference (Euro PCR)
‐ Japan: Clinical tests still in progress

Nobori, Drug eluting stent◆「DuraHeart」‐ The U.S.: University of Michigan in preparation for implant‐ Japan: Clinical tests will start in this fiscal year◆「Anaconda」‐ The U.S. : FDA approved the shift to phase II of clinical tests

The patient of
DuraHeart, LVAS
(the right) 15

The mid-term management plan started as planned16

IR Contact
TERUMO Corporation
Corporate Communication (IR) Dept.
E-mail: CCD@terumo.co.jp

This document contains forward-looking statements that reflect
management’s current views with respect to certain future events andfinancial performance. Actual results may differ materially from thoseprojected or implied in the forward-looking statements and from historicaltrends. Furthermore, certain forward-looking statements are based uponassumptions of future events that may not prove to be accurate. Factorsthat could cause actual results to differ materially from those projected orimplied in any forward-looking statements include, but are not limited to,changes in overall economic conditions, fluctuations of foreign exchange
rates, and intensifying price competition in the markets for our products.
17